EVALUATION OF ANTI-GOUT ACTIVITY OF TANGERETIN, A POLYMETHOXYLATED FLAVONE IN HYPERURICAEMIA AND ACUTE GOUTY ARTHRITIS RAT MODELS

Background: Uric acid crystals that accumulate in the joints can develop gouty arthritis, a painful and crippling form of arthritis that results in both acute inflammation and long-term joint damage. The current therapies focus on symptom relief and uric acid level lowering. Novel therapeutic strategies, however, are required since they have fewer adverse effects and greater efficacy. The purpose of this abstract is to discuss the assessment of the therapeutic efficacy of Tangeretin in potassium oxonate-induced hyperuricemia model of Wister rats. Determination of the anti-gout activity of Tangeretin in monosodium urate (MSU)-induced gout model of Wister rats. Methods: Information on the anti-inflammatory and antioxidant capabilities of tangeretin and its influence on gout-related pathways was gathered by conducting a thorough search of the scholarly literature. Results: By blocking important inflammatory mediators and pathways such nuclear factor-kappa B (NF-B) and interleukin-1 (IL-1), tangeretin has shown anti-inflammatory effects. Additionally, its strong antioxidant qualities assist in reducing oxidative stress, a factor in the aetiology of gout. Furthermore, tangeretin has the ability to alter purine metabolism, which would lower uric acid synthesis and promote its elimination. Tangeretin is emerging as a promising therapy option for gouty arthritis because of its anti-inflammatory, antioxidant, and possible uric acid-regulating effects. To assess its security, effectiveness, and ideal dosage for gout patients, more study is required, including pre-clinical and clinical trials. Tangeretin could provide a fresh and supplementary strategy to the treatment of gout, enhancing the quality of life for those who experience this excruciating ailment, if it is found to be effective.